This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock Get the Latest News and Ratings for BOLD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Audentes Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up BOLD Analyst Ratings Over TimeTypeCurrent Forecast5/4/24 to 5/4/251 Month Ago4/4/24 to 4/4/253 Months Ago2/4/24 to 2/3/251 Year Ago5/5/23 to 5/4/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)2 Buy rating(s)2 Buy rating(s)3 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price TargetN/A$23.00$23.00$23.00Forecasted UpsideN/A1,662.45% Upside936.04% Upside145.99% UpsideConsensus RatingHoldModerate BuyModerate BuyBuy BOLD Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BOLD Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Audentes Therapeutics Stock vs. The CompetitionTypeAudentes TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.00 2.81 2.54Consensus RatingHoldModerate BuyModerate BuyPredicted UpsideN/A3,338.15% Upside17.54% UpsideNews Sentiment RatingNeutral NewsSee Recent BOLD NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails12/13/2024Guggenheim2 of 5 starsM. SchmidtSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/22/2024Piper Sandler2 of 5 stars Initiated CoverageOverweight$20.00+98.22%4/22/2024Leerink Partners1 of 5 stars Initiated CoverageOutperform$25.00+147.77%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:38 PM ET. BOLD Forecast - Frequently Asked Questions Should I buy or sell Audentes Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There is currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BOLD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BOLD, but not buy additional shares or sell existing shares. Does Audentes Therapeutics's stock price have much downside? According to analysts, Audentes Therapeutics's stock has a predicted downside of -100.00% based on their 12-month stock forecasts. Do Wall Street analysts like Audentes Therapeutics more than its competitors? Analysts like Audentes Therapeutics less than other "medical" companies. The consensus rating for Audentes Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BOLD compares to other companies. Stock Forecasts and Research Tools Related Companies ProQR Therapeutics Stock Forecast Actuate Therapeutics Stock Forecast Journey Medical Stock Forecast AC Immune Stock Forecast TuHURA Biosciences Stock Forecast Lexicon Pharmaceuticals Stock Forecast Korro Bio Stock Forecast Aldeyra Therapeutics Stock Forecast Larimar Therapeutics Stock Forecast LifeVantage Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:BOLD) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BOLD Stock Free BOLD Stock Alerts